Desitin Pharmaceuticals GmbH – galenic innovation for over 40 years
2011 Levetiracetam Desitin
The first levetiracetam minitablets worldwide (approved administration form: film-coated granules in sachets)
2010 Sumavel® DosePro®
The first ready-to-use, needle free injector for sumatriptan in Europe*
2009 Topiramat Desitin quadro
The first quartered topiramate tablet worldwide
2008 Apydan extent
The first modified release formulation for oxcarbazepine worldwide
1999 Orfiril® long 1000 mg
The first valproate administration form of this strength worldwide
1998 Orfiril® long 150 mg / 300 mg
The first sustained-release valproate minitablets worldwide
1996 Orfiril® solution for injection
The first ready-to-use valproate solution for injection worldwide
1984 Timonil® 300 sustained-release
The first sustained-release formulation for carbamazepine worldwide
1978 Orfiril® 300 sustained-release
The first sustained-release valproate formulation worldwide
1972 Phenhydan® infusion concentrate
The first dilutable phenytoin infusion concentrate worldwide
1970 Liskantin® syrup
The first oral administration form (liquid) for primidone worldwide
1967 Phenhydan® solution for injection
The first ready-to-use phenytoin solution for injection worldwide
*DoseProTM Technology invented and owned by Zogenix, Inc.
Note: In UK Orfiril® long and Orfiril® solution for injection are marketed under the brand name of Episenta®▼ (sodium valproate prolonged release) or Episenta®▼ Solution for Injection (sodium valproate).
In the UK Levetiracetam Desitin is marketed under the brand name of Desitrend® (levetiracetam)
None of the other products shown are available in the UK at this time from Desitin.
DESITIN ARZNEIMITTEL GmbH was founded in Berlin in 1919. We developed and successfully introduced the still frequently used Desitin® ointment as our first product. In 1945, Desitin relocated to Hamburg, where the development and sales of medication for illnesses of the central nervous system (CNS) began. The company became a specialist supplier and competent partner […]
Click to Expand
Desitin concentrates its marketing efforts on the European continent. In a number of countries (key countries mainly in the UK, Scandinavia and Eastern Europe as well as in Switzerland) Desitin is present with own sales forces, whereas in other countries licencees and partners distribute Desitin’s products.
Click to Expand
Desitin is focused on pharmaceuticals for the treatment of epilepsy. It is the only manufacturer that offers the almost entire spectrum of products recommended by the WHO for the treatment of epilepsy. It should be noted that not all products are available in all countries. Desitin not only offers a wide range of different therapeutics, […]
Click to Expand
Three active ingredients play a major role in Desitin‘s own developments for epilepsy: Valproic acid, which is the first-line therapy for generalized seizures, Carbamazepine, which is of the same relevance for focal seizures, and Oxcarbazepine the more modern alternative to Carbamazepine.
Click to Expand
Medium-sized, specialized pharmaceutical company Founded nearly 100 years ago in Berlin Independent, family-owned, profitable company, based in Hamburg About 300 employees in development, production, sales, medicine, marketing and administration Established as a specialist in the field of epilepsy Addition of further CNS indications Fully integrated pharmaceutical company Incorporating sales & marketing, commercial, medical affairs and […]
Click to Expand
Desitin Pharma Ltd disclosure of payments to Health Care Professionals (HCPs), Donations and Grants Date of Preparation April 2019
Click to Expand
Pharmaceutical innovations developed by Desitin as well as the launch of new chemical entities licenced from partners represent corporate milestones throughout Desitin’s history. None of the products shown are available in the UK at this time from Desitin.
Click to Expand
Desitin’s straightforward approach together with the quality of its products from own development and licensors consequently lead to its high reputation within its main target group – neurologists – as shown in the results of the survey performed in Germany in 2013. Desitin is starting to build a reputation in the UK.
Click to Expand
Desitin Pharmaceuticals GmbH – galenic innovation for over 40 years 2011 Levetiracetam Desitin The first levetiracetam minitablets worldwide (approved administration form: film-coated granules in sachets) 2010 Sumavel® DosePro® The first ready-to-use, needle free injector for sumatriptan in Europe* 2009 Topiramat Desitin quadro The first quartered topiramate tablet worldwide 2008 Apydan extent The first modified release formulation […]
Click to Expand
Pharmaceuticals are developed, manufactured, procured, and tested at Desitin’s Hamburg site under modern conditions and then shipped to our customers worldwide. The comprehensive laws, regulations, and standards conforming to AMG, AMWHV, cGXP, etc. are mapped in a modern process-oriented and flexible organisation. Falsified Medicines Directive (Directive 2016/62/EU) Desitin is compliant with Directive 2016/62/EU. All products […]
Click to Expand
Relevant information about our clinical development activities is provided below. At Desitin, we are proud of the fact that for decades we have consistently produced global innovations that have considerably improved and simplified drug treatment for doctors and patients, and have already become standard treatments. These innovations, which were and are always developed in close […]
Click to Expand